Showing results (151-160 of 179) with videos related to
Sort By:
Pageof 18
The Journal of Urology|August 20, 2008
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJames L Gulley, Jeanny B Aragon-Ching, Seth M Steinberg, et al.BJU International|January 22, 2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancerJeanny B Aragon-Ching, Lokesh Jain, James L Gulley, et al.Pediatric Radiology|March 19, 2020
Accuracy of subjective vesicoureteral reflux timing assessment: supporting new voiding cystourethrogram guidelinesDabin Ji, Derrick E Ridley, J Damien Grattan-Smith, et al.The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.Cancer Biology & Therapy|December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumorsWilliam L Dahut, Nehal J Lakhani, James L Gulley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerWilliam L Dahut, James L Gulley, Philip M Arlen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomasJohn L Marshall, James L Gulley, Philip M Arlen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerPhilip M Arlen, James L Gulley, Catherine Parker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerPhilip W Kantoff, Thomas J Schuetz, Brent A Blumenstein, et al.The Journal of Urology|January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg, Maha H Hussain, James L Gulley, et al.Pageof 18